The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1195-1200

  Kawasaki, Masayuki ^a   Nakanishi, Yoichi ^a   Kuwano, Kazuyoshi ^a   Yatsunami, Jun ^a   Takayama, Koichi ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PROTEIN P53; VINDESINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030760737     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer Stat., 44: 7-26, 1994.
2. Hansen, H. H. Management of small-cell cancer of the lung. Lancet, 339: 846-849, 1992.
3. Rapp, E., Pater, J. L., Willam, A., Cormier, Y., Murray, N., Evans, W. K., Hodson, D. I., Clark, D. A., Feld, R., and Arnold, A. M. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J. Clin. Oncol., 6: 633-641, 1988.
4. Cellerino, R., Tummarello D., Guidi, F., Isidori, P., Raspugli, M., Biscottini, B., and Fatati, G. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J. Clin. Oncol., 9: 1453-1461, 1991.
5. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levin. M., Pass. H., Gazdar. A. F., and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-494, 1989.
6. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.
7. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
8. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi. R., and Shirakusa, T. Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. (Bethesda), 85: 2018-2023, 1993.
9. Brambilla, E., Gazzeri, S., Moro, D., Fromentel, C. C., Gouyer, V., Jacrot, M., and Brambilla, C. Immunohistochemical study of p53 in human lung carcinomas. Am. J. Pathol., 143: 199-210, 1993.
10. Ebina, M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54: 2496-2503, 1994.
11. Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., and Hong, W. K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J. Clin. Oncol., 13: 1893-1903, 1995.
12. Fujino, M., Dosaka-Akita, H., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. Prognostic significance of p53 and ras p21 expression in non-small cell lung cancer. Cancer (Phila.), 76: 2457-2463, 1995.
13. Nishio, M., Koshikawa, T., Kuroishi, T., Suyama, M., Uchida, K., Takagi, Y., Washimi, O., Sugiura, T., Ariyoshi, Y., Takahashi, T., Ueda, R., and Takahashi, T. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancer. J. Clin. Oncol., 14: 497-502, 1996.
14. Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., Kris, M., and Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55: 5038-5042, 1995.
15. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
16. Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 6: 1775-1778, 1991.
17. D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., Gazdar, A., and Minna, J. D. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7: 339-346, 1992.
18. Lohmann, D., Pütz, B., Reich, U., Böhm, J., Präuer, H., and Höfler, H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am. J. Pathol., 142: 907-915, 1993.
19. Levin, D., Wicks, A., and Ellis, J. Transbronchial lung biopsy via the fiberoptic bronchoscope. Am. Rev. Respir. Dis., 110: 4-12, 1974.
20. Mountain, C. F. A new international classification system for lung cancer. Chest, 89 (Suppl.): 225S-233S, 1986.
21. Shin, R. W., Iwaki, T., Kitamoto, T., and Tateishi, J. Hydrated autoclave pretreatment enhances TAU immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. Lab. Invest., 64: 693-702, 1991.
22. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting the results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
23. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
24. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827-830, 1992.
25. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Piywes, R., and Prives, C. Wild-type p53 activates transcription in vitro. Nature (Lond.), 358: 83-86, 1992.
26. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
27. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA. 90: 5742-5746, 1993.
28. Ellege, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E., Robert, N., Tormey, D. C., and Allred, D. C. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst. (Bethesda), 87: 1254-1256, 1995.
29. Zwelling, L. A., and Kohn, K. W. Mechanism of action of. cis-dichlorodiammineplatinum (II). Cancer Treat. Rep., 63: 1439-1444, 1979.
30. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. (Bethesda), 82: 749-755, 1990.
31. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W-W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
32. Righetti, S. C., Torre, G. D., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Bohm, S., Bresciani, G. L., Spatti, G., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
33. 2-M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
34. Gonzalez, B. M., Garcia, G. C., Zamora, P,. de Garcia, P. M. L., Feliu, J., Ordonez, A., Artal, A., Garrido, P., and Chacon, J. I. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years. Am. J. Clin. Oncol., 15: 23-28, 1992.